San DiegoOtherBiotechnologyHealth CareTherapeutics
Investors
Digitalis Ventures
Description
Gallant Therapeutics announced it had raised more than $15 million in Series A funding from a leading investor syndicate, enabling the company to further its mission to make U.S. Food and Drug Administration-approved, stem cell therapies a reality for pets.
Who to call at Gallant, and when
A new round usually means Gallant is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Gallant raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Gallant, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Gallant. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Gallant
Location
10865 Road to the Cure, Ste 101
San Diego, California, United States
About
Gallant is a regenerative medicine company pioneering veterinary therapies that restore health at the source. We’re developing a pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies to address chronic conditions in dogs and cats—including feline chronic gingivostomatitis (FCGS), osteoarthritis, chronic kidney disease, and atopic dermatitis. Our first product, based on a proprietary uterine-derived stem cell platform, is on track for conditional FDA approval in 2026. Led by industry pioneers in veterinary regenerative medicine, Gallant combines science, purpose, and compassion to help pets live healthier, more vibrant lives.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Gallant raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoOtherBiotechnologyHealth CareTherapeutics